Differential cytokine, chemokine and growth factor expression in phenotypes of chronic lung allograft dysfunction

Transplantation

Volumn 99, Issue 1, 2015, Pages 86-93

  Verleden, Stijn E ^a   Ruttens, David ^a   Vos, Robin ^a   Vandermeulen, Elly ^a   Moelants, Eva ^b   Mortier, Anneleen ^b   Van Raemdonck, Dirk E ^a   Proost, Paul ^b   Schols, Dominique ^b   Verleden, Geert M ^a   Vanaudenaerde, Bart M ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CHEMOKINE; CXCL11 CHEMOKINE; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GROWTH FACTOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 3; UNCLASSIFIED DRUG; VASCULOTROPIN; SIGNAL PEPTIDE;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BRONCHIOLITIS OBLITERANS; CHRONIC LUNG ALLOGRAFT DYSFUNCTION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE DIFFERENTIAL COUNT; LUNG DISEASE; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHENOTYPE; POSTOPERATIVE PERIOD; PROTEIN EXPRESSION; RESTRICTIVE ALLOGRAFT SYNDROME; TRANSBRONCHIAL BIOPSY; UPREGULATION; ALLOGRAFT; BIOPSY; CHRONIC DISEASE; CLASSIFICATION; COMPARATIVE STUDY; EOSINOPHIL; IMMUNOLOGY; KAPLAN MEIER METHOD; LEUKOCYTE COUNT; LUNG TRANSPLANTATION; MIDDLE AGED; MORTALITY; NEUTROPHIL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ALLOGRAFTS; BIOPSY; BRONCHIOLITIS OBLITERANS; BRONCHOALVEOLAR LAVAGE FLUID; CHEMOKINES; CHRONIC DISEASE; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EOSINOPHILS; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; LEUKOCYTE COUNT; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; NEUTROPHILS; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84920273668     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000269     Document Type: Article

References (21)

1. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 2012;31:1073.
2. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002;21:297.
3. Vanaudenaerde BM, Meyts I, Vos R, et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J 2008;32:832.
4. Verleden SE, Vos R, Mertens V, et al. Heterogeneity of chronic lung allograft dysfunction: insights from protein expression in broncho alveolar lavage. J Heart Lung Transplant 2011;30:667.
5. Sato M, Waddell TK, Wagnetz U, et al. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. J Heart Lung Transplant 2011;30:735.
6. Verleden GM, Vos R, Verleden SE, et al. Survival determinants in lung transplant patients with chronic allograft dysfunction. Transplantation 2011;92:703.
7. Verleden SE, Ruttens D, Vandermeulen E, et al. Bronchiolitis obliterans syndrome and restrictive allograft syndrome: do risk factors differ? Transplantation 2013;95:1167.
8. Sato M, Hwang DM, Ohmori-Matsuda K, et al. Revisiting the pathologic finding of diffuse alveolar damage after lung transplantation. J Heart Lung Transplant 2012;31:354.
9. Verleden SE, Ruttens D, Vandermeulen E, et al. Elevated bronchoalveolar lavage eosinophilia correlates with poor outcome after lung transplantation. Transplantation 2013.
10. Greer M, DierichM, deWall C, et al. Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients. Am J Transplant 2013;13:911.
11. Mantovani A, Bonecchi R, Locati M. Tuning inflammation and immunity by chemokine sequestration: decoys andmore. NatRev Immunol 2006;6:907.
12. de Jong PA, Vos R, Verleden GM, Vanaudenaerde BM, Verschakelen JA. Thin-section computed tomography findings before and after azithromycin treatment of neutrophilic reversible lung allograft dysfunction. Eur Radiol 2011;21:2466.
13. Vos R, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE, Verleden GM. Transient airway colonization is associated with airway inflammation after lung transplantation. Am J Transplant 2007;7:1278.
14. Rincon M, Irvin CG. Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci 2012;8:1281.
15. Allen JG, Lee MT, Weiss ES, Arnaoutakis GJ, Shah AS, Detrick B. Preoperative recipient cytokine levels are associated with early lung allograft dysfunction. Ann Thorac Surg 2012;93:1843.
16. Lu KC, Jaramillo A, Lecha RL, et al. Interleukin-6 and interferon-gamma gene polymorphisms in the development of bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2002;74:1297.
17. Bharat A, Narayanan K, Street T, et al. Early posttransplant inflammation promotes the development of alloimmunity and chronic human lung allograft rejection. Transplantation 2007;83:150.
18. Langenbach SY, Zheng L,McWilliams T, et al. Airway vascular changes after lung transplant: potential contribution to the pathophysiology of bronchiolitis obliterans syndrome. J Heart Lung Transplant 2005;24:1550.
19. Meyer KC, Cardoni AL, Xiang Z, Cornwell RD, Love RB. Vascular endothelial growth factor in human lung transplantation. Chest 2001;119:137.
20. Martinu T, Howell DN, Davis RD, Steele MP, Palmer SM. Pathologic correlates of bronchiolitis obliterans syndrome in pulmonary retransplant recipients. Chest 2006;129:1016.
21. Chamberlain D, Maurer J, Chaparro C, Idolor L. Evaluation of transbronchial lung biopsy specimens in the diagnosis of bronchiolitis obliterans after lung transplantation. J Heart Lung Transplant 1994;13:963.